Brief: Modulight Says Study Confirms Benefits Of Co's Technology For Ovarian Cancer

Modulight Oyj

07/09/2023 07:15

Sept 7 (Reuters) - Modulight Oyj  MODUL.HE :
    * SAID ON WEDNESDAY STUDY CONFIRMS BENEFITS OF MODULIGHT'S
TECHNOLOGY AND PHOTOIMMUNOTHERAPY FOR OVARIAN CANCER
    * THE VARIATION IN TREATMENT RESPONSE WAS SIGNIFICANTLY
REDUCED BY
ABOUT 22% AND OVERALL TUMOR CONTROL IMPROVED WITHOUT SIDE
EFFECTS

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nMFN1XDLtD
 Further company coverage:  MODUL.HE  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))